Enhancement of recovery from psychiatric illness by methylfolate
| Autor: | P.S.A Godfrey, B.K. Toone, T. Bottiglien, M. Laundy, E.H. Reynolds, M.W.P. Carney, T.G. Flynn, I. Chanarin |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male medicine.medical_specialty Erythrocytes medicine.medical_treatment Folic Acid Deficiency Placebo law.invention Folic Acid Double-Blind Method Randomized controlled trial law medicine Humans Psychiatry Depression (differential diagnoses) Aged Randomized Controlled Trials as Topic Depressive Disorder Chemotherapy General Medicine Middle Aged Mental illness medicine.disease Clinical trial Vitamin B 12 Methotrexate Schizophrenia Female Psychopathology |
| Zdroj: | The Lancet. 336:392-395 |
| ISSN: | 0140-6736 |
| DOI: | 10.1016/0140-6736(90)91942-4 |
| Popis: | 41 (33%) of 123 patients with acute psychiatric disorders (DSM III diagnosis of major depression or schizophrenia) had borderline or definite folate deficiency (red-cell folate below 200 micrograms/l) and took part in a double-blind, placebo-controlled trial of methylfolate, 15 mg daily, for 6 months in addition to standard psychotropic treatment. Among both depressed and schizophrenic patients methylfolate significantly improved clinical and social recovery. The differences in outcome scores between methylfolate and placebo groups became greater with time. These findings add to the evidence implicating disturbances of methylation in the nervous system in the biology of some forms of mental illness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|